Related references
Note: Only part of the references are listed.Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma
JF DiJoseph et al.
CLINICAL CANCER RESEARCH (2006)
Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies
JF DiJoseph et al.
BLOOD (2004)
Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma
JF DiJoseph et al.
CLINICAL CANCER RESEARCH (2004)
Antibody pharmacokinetics and pharmacodynamics
ED Lobo et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
Increasing the affinity of a human IgG1, for the neonatal Fc receptor: Biological consequences
WF Dall'Acqua et al.
JOURNAL OF IMMUNOLOGY (2002)
Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotug) therapy
P Rajvanshi et al.
BLOOD (2002)
Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia
PR Hamann et al.
BIOCONJUGATE CHEMISTRY (2002)
Pharmacokinetics of murine anti-human CD3 antibodies in man are determined by the disappearance of target antigen
RT Meijer et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
General pharmacokinetic model for drugs exhibiting target-mediated drug disposition
DE Mager et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2001)
Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse
JA Dowell et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2001)
Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas
A Heider et al.
ANTI-CANCER DRUGS (2001)
Understanding and exploiting nature's chemical arsenal: The past, present and future of calicheamicin research
JS Thorson et al.
CURRENT PHARMACEUTICAL DESIGN (2000)
Share Paper
